BG
TRVI icon

Bellevue Group’s Trevi Therapeutics TRVI Stock Holding History

Bellevue Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,603
Closed -$95.2K – 191
2025
Q4 		$95.2K Buy
+7,603
New +$87.9K ﹤0.01% 165

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Bellevue Group's TRVI Position: Q1 2026 in Review

Bellevue Group sold out of Trevi Therapeutics (TRVI) in Q1 2026, closing a stake of 7,603 shares — an estimated $95.2K sold.

Bellevue Group first reported a position in TRVI in Q4 2025 and held it in 1 quarter. The position peaked at $95.2K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Bellevue Group reported no remaining Trevi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bellevue Group sold 7,603 Trevi Therapeutics shares in Q1 2026, an estimated $95.2K.
  • Bellevue Group first reported a position in Trevi Therapeutics in Q4 2025 and held it in 1 quarter.
  • Bellevue Group's Trevi Therapeutics position peaked at $95.2K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.